N-(2-chloro-5-(3-((2-methoxylethyl)(methyl)amino)quinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide | 1201842-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(2-chloro-5-(3-((2-methoxylethyl)(methyl)amino)quinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide
• 英文别名: N-(2-chloro-5-(3-((2-methoxyethyl)(methyl)amino)-6-quinoxalinyl)-3-pyridinyl)-4-fluorobenzenesulfonamide；N-[2-chloro-5-[3-[2-methoxyethyl(methyl)amino]quinoxalin-6-yl]pyridin-3-yl]-4-fluorobenzenesulfonamide
• CAS: 1201842-85-4
• 化学式: C₂₃H₂₁ClFN₅O₃S
• 分子量: 501.969
• InChiKey: FUCFMCKCHUSEOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-(2-甲氧基乙基)甲基胺 、 N-(2-chloro-5-(3-fluoroquinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以31%的产率得到N-(2-chloro-5-(3-((2-methoxylethyl)(methyl)amino)quinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide
  参考文献：
  名称：

  Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives

  摘要：

  The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3'-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives. In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound.

  DOI：

  10.1021/jm200386s

文献信息

• INHIBITORS OF PI3 KINASE
  申请人：Bo Yunxin Y.

  公开号：US20110092504A1

  公开（公告）日：2011-04-21

  The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X 1 , X 2 , R 1 and Z are as defined herein.

  本发明涉及式（I）的化合物，或其药学上可接受的盐；使用该化合物治疗疾病或病症的方法，例如癌症；以及含有该化合物的制药组合物，其中Q、X1、X2、R1和Z的定义如本文所述。
• US8415376B2
  申请人：——

  公开号：US8415376B2

  公开（公告）日：2013-04-09
• [EN] INHIBITORS OF PI3 KINASE<br/>[FR] INHIBITEURS DE LA PI3 KINASE
  申请人：AMGEN INC

  公开号：WO2009155121A2

  公开（公告）日：2009-12-23

  The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1, X2, R1 and Z are as defined herein.
• Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives
  作者：Nobuko Nishimura、Aaron Siegmund、Longbin Liu、Kevin Yang、Marian C. Bryan、Kristin L. Andrews、Yunxin Bo、Shon K. Booker、Sean Caenepeel、Daniel Freeman、Hongyu Liao、John McCarter、Erin L. Mullady、Tisha San Miguel、Raju Subramanian、Nuria Tamayo、Ling Wang、Douglas A. Whittington、Leeanne Zalameda、Nancy Zhang、Paul E. Hughes、Mark H. Norman

  DOI：10.1021/jm200386s

  日期：2011.7.14

  The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3'-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives. In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound.